Avidity Biosciences

Historical price data

Avidity Biosciences is a clinical-stage biotech with a mission to profoundly improve lives by delivering a new class of targeted RNA therapeutics. Its core innovation is the AOC platform, which overcomes the historic delivery barriers of oligonucleotide therapies by using antibodies as tissue-specific delivery vehicles. The company is executing a focused strategy, advancing a pipeline of AOCs for rare muscle diseases with high unmet need, aiming to establish clinical proof-of-concept that can unlock the platform's potential across a broad range of therapeutic areas. Recent clinical data readouts have generated significant investor confidence, reflected in its multi-billion dollar valuation.

Proprietary Antibody Oligonucleotide Conjugate (AOC™) platform that combines the tissue-targeting specificity of monoclonal antibodies with the precision of oligonucleotide therapeutics to deliver RNA-modulating payloads directly to diseased cells.

Competes with traditional oligonucleotide firms (Ionis, Sarepta) limited by delivery, and AAV-based gene therapy companies (Pfizer, Solid). Avidity's key differentiator is its targeted AOC delivery, which promises higher efficacy, better safety, and re-dosability compared to these modalities, positioning it uniquely in the genetic medicine space.